The approval was based on a clinical trial comparing brentuximab vedotin plus conmbination
chemotherapy (Adriamycin [doxorubicin], vinblastine and
dacarbazine, or AVD) vs a
chemotherapy - only regimen commonly used to treat cHL (AVD plus bleomycin, also known as ABVD).